Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Hemosol reacquires all rights to oxygen therapeutic

Oct. 14, 1999

Risedronate featured in JAMA; Sweden issues first approval for osteoporosis

Oct. 14, 1999

Modulators of PTPases and their use described by Novo Nordisk

Oct. 14, 1999

In vitro and in vivo testing shows chondrogenic effects for TAK-778

Oct. 14, 1999

Ixion Biotechnology awarded NIH grant for type I diabetes research

Oct. 13, 1999

Selective beta3-adrenoceptor agonists in development at Merck

Oct. 12, 1999

RPR sublicenses hormone replacement products to Novartis

Oct. 12, 1999

FDA approves seven-day HRT patch

Oct. 8, 1999

Duramed and Solvay team up to promote hormone products

Oct. 8, 1999

TAP to develop xanthine oxidase inhibitor from Teijin in North America

Oct. 7, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...